Rethinking the Role of Co-morbidities in Transthyretin Cardiac Amyloidosis: Cinderella or Princess? The Case of Anemia and Iron Deficiency
-
Published:2024-10
Issue:
Volume:229
Page:79-80
-
ISSN:0002-9149
-
Container-title:The American Journal of Cardiology
-
language:en
-
Short-container-title:The American Journal of Cardiology
Author:
Sanna Giuseppe D.ORCID,
Milani Paolo,
Palladini Giovanni
Reference10 articles.
1. 2023 ACC Expert Consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology solution set oversight committee;Kittleson;J Am Coll Cardiol,2023
2. Milani P, Fabris F, Mussinelli R, Sanna GD, Basset M, Benvenuti P, Bellofiore C, Nanci M, Nuvolone M, Attanasio A, Guida G, Perlini S, Foli A, Merlini G, Palladini G. Delayed identification of monoclonal protein is associated with early death in isolated cardiac AL amyloidosis [published online July 11, 2024]. Amyloid doi: 10.1080/13506129.2024.2374904.
3. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction;Mentz;J Am Coll Cardiol,2014
4. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure;McDonagh;Eur Heart J,2023
5. Impact of anemia on mortality and morbidity in transthyretin amyloid cardiomyopathy;Wardhere;Am J Cardiol,2024